Wegovy 1mg to 1.7mg: the dose step most people misunderstand

The biggest myth: that moving up is just a formality

A lot of people arrive at the 1mg mark expecting the next pen to be handed over automatically after four weeks. That is not how it works, and assuming it is can lead to real frustration. Progression through Wegovy's titration schedule is a clinical decision, not a subscription item. Your prescriber is asking a specific question at each step: did you tolerate this dose well enough, and is continuing to increase the right move for you?

At 1mg, many patients are already experiencing meaningful appetite suppression, and some find that side effects (nausea, looser stools, some fatigue) have only just settled. Moving to 1.7mg before those effects have genuinely resolved is not good clinical practice, and a conscientious prescriber will take that into account. The schedule sets the minimum time between steps; it does not set a deadline by which you must have progressed.

It is also worth knowing that 1.7mg is not just a waypoint, and for patients who find 2.4mg difficult to tolerate, the guidance recognises that it can serve as a sustained therapeutic dose. The NHS medicines page for semaglutide sets out the full titration picture in plain terms and is worth reading alongside whatever your prescriber advises.

What changes physiologically at 1.7mg compared with 1mg

Semaglutide works as a GLP-1 receptor agonist: it mimics a gut hormone that signals fullness, slows the rate at which the stomach empties and acts on appetite-regulating centres in the brain. The dose-response relationship is real, higher doses generally produce a stronger effect on appetite and, in the trial data, greater average weight loss over time. The STEP 1 trial, published in the New England Journal of Medicine, reported around 15% average weight reduction over 68 weeks at the 2.4mg maintenance dose, with patients working through the same titration schedule including the 1.7mg step.

The 1mg-to-1.7mg increase is proportionally larger than some of the earlier steps, which is one reason GI symptoms can resurface temporarily. Nausea and loose stools that had quietened at 1mg sometimes return for a week or two after moving up. This is expected and usually brief, but it is not trivial, eating slowly, sticking to smaller portions and keeping well hydrated all help. If symptoms are more than mild, that is exactly the kind of thing to raise with your prescriber rather than just waiting it out.

One practical habit worth building: check the injection site you used last week and choose a different area this time, abdomen, thigh and upper arm are all suitable, and rotating between them reduces local skin irritation that can make any dose step feel rougher than it needs to be. It takes under a minute and makes a genuine difference.

How prescribers approach the step up, and what to expect at a reputable online pharmacy

A responsible prescriber looks at two things before agreeing to move from 1mg to 1.7mg: how you have got on at 1mg, and any changes in your broader health picture since the last review. At nume, every repeat order goes through clinical re-review by a GPhC-registered Independent Prescriber before it is dispensed. There are no automatic renewals. Your prescriber reads your update, considers the evidence and makes the call. That also applies to dose increases, which require supporting information before being confirmed.

If you are transferring from another provider and are already on 1mg, you can find out more about how Wegovy as a treatment is managed through a regulated UK service, or read about the full dose ladder to understand where 1.7mg sits in context. Patients curious about what moving to the maintenance dose involves can look at the 1.7mg to 2.4mg transition when the time comes.

Cost is a practical reality at this stage too: private Wegovy pricing is set per pen, and as you move up the schedule the pen strength changes. For a factual picture of what private treatment typically costs across the titration journey, the Wegovy cost context page covers what market prices look like and what a legitimate private prescription includes. The right question at this stage is not which provider charges least, it is whether the clinical oversight matches the standard these medicines require.

When 1.7mg is the final dose, not a stepping stone

Not everyone reaches 2.4mg, and that is not a failure. NICE's recommendation for semaglutide under TA875 sets out that if fewer than 5% of body weight has been lost after six months on the maintenance dose, continuing treatment should be reviewed, but it also acknowledges that tolerability is a legitimate clinical reason to remain at a lower dose. Some patients do well at 1.7mg and stay there with their prescriber's agreement.

If side effects at 1.7mg are persistent or significant, the clinical conversation should happen promptly. Staying on a dose that is causing consistent discomfort without telling your prescriber is one of the most common mistakes people make during titration. The support is there to be used. If you have questions about how this step is managed at a clinician-led service, our FAQs cover a lot of the practical detail, and the team is reachable through our contact page for anything more specific.